Prospective Observational Scientific Study Investigating Bone Loss Experience in Europe (POSSIBLE EU®) is an ongoing longitudinal cohort study that utilises physician- and patient-reported measures to describe the characteristics and management of postmenopausal women on bone loss therapies. We report the study design and baseline characteristics of 3,402 women recruited from general practice across five European countries.
The POSSIBLE EU® is a study describing the characteristics and management of postmenopausal women receiving bone loss medications.
Between 2005 and 2008, general practitioners enrolled postmenopausal women initiating, switching or continuing treatment with bone loss treatment in France, Germany, Italy, Spain and the UK. Patients and physicians completed questionnaires at study entry and at 3-month intervals, for 1 year.
Of 3,402 women enrolled (mean age 68.2 years [SD] 9.83), 96% were diagnosed with low bone mass; 55% of these using dual energy X-ray absorptiometry. Most women (92%) had comorbidities. Mean minimum T score (hip or spine) at diagnosis was −2.7 (SD 0.89; median −2.7 [interquartile range, −3.2, −2.2]) indicating low bone mineral density. Almost 40% of the women had prior fractures in adulthood, mostly non-vertebral, non-hip in nature, 30% of whom had at least two fractures and more than half experienced moderate/severe pain or fatigue. Bisphosphonates were the most common type of bone loss treatment prescribed in the 12 months preceding the study.
POSSIBLE EU® characterises postmenopausal women with low bone mass, exhibiting a high rate of prevalent fracture, substantial bone fragility and overall comorbidity burden. Clinical strategies for managing osteoporosis in this population varied across the five participating European countries, reflecting their different guidelines, regulations and standards of care.
International Osteoporosis Foundation (2008) Osteoporosis in the European Union in 2008: ten years of progress and ongoing challenges. Available at http://www.iofbonehealth.org/publications/eu-policy-report-of-2008.html. Accessed 8 April 2009
Seeman E, Compston J, Adachi J et al (2007) Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporosis Int 18:711–719 CrossRef
Barrett-Connor E, Ensrud K, Tosteson A et al (2009) Design of the POSSIBLE US™ study: postmenopausal women’s compliance and persistence with osteoporosis medications. Osteoporosis Int 20:463–472 CrossRef
The EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208 CrossRef
EuroQol Group EQ-5D. In. EuroQol Group Rotterdam, The Netherlands
Silverman S (2000) The Osteoporosis Assessment Questionnaire (OPAQ): a reliable and valid disease-targeted measure of health-related quality of life (HRQOL) in osteoporosis. Qual Life Res 9:767–774 CrossRef
Guideline for prevention and treatment of Op SINOSSI. Available at http://www.siommms.it. Last accessed 12 March 2009
Agence Francaise de Securite Sanitaire des Produits de Sante. Available at http://www.afssaps.fr/var/afssaps_site/storage/original/application/2f4831c7ee9d9bd6fda336a26b6500c6.pdf Last accessed 17 April 2009
Evidenz-basierte Konsensus-Leitlinien zur Osteporose (2009) Available at http://www.dv-osteologie.org/. Last accessed 17 April
National Institute for Health and Clinical Excellence (NICE) (2009) Available at http://www.nice.org.uk/guidance/index.jsp?action=byID&r=true&o=11621. Last accessed 14 April
Sociedad Española de Investigaciones Óseas y Metabolismo Mineral - SEIOMM (2009) Available at http://www.seiomm.org/documentos/osteoporosis_es_en.pdf. Last accessed 14 April
Lindsay R, Delmas P, Boonen S, Diez-Perez A, Dedrick R, Saag KG (2008) Regional differences in the management of osteoporosis in women. ASBMR abstract book 2008. SU287
- Baseline observations from the POSSIBLE EU® study: characteristics of postmenopausal women receiving bone loss medications
Neu im Fachgebiet Orthopädie und Unfallchirurgie
Mail Icon II